Italia markets closed
FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
37.986,40 +211,02 (+0,56%) Nasdaq
15.282,01 -319,49 (-2,05%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,24 +0,51 (+0,62%) Bitcoin EUR
59.895,71 +491,82 (+0,83%)
UCB SA (UCB.BR)
Brussels - Brussels Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
Alla chiusura: 05:35PM CEST
| Chiusura precedente | 120,00 |
| Aperto | 119,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 118,40 - 121,40 |
| Intervallo di 52 settimane | 65,40 - 122,60 |
| Volume | |
| Media Volume | 314.796 |
| Capitalizzazione | 23,001B |
| Beta (5 anni mensile) | 0,40 |
| Rapporto PE (ttm) | 68,86 |
| EPS (ttm) | 1,76 |
| Prossima data utili | 28 feb 2024 |
| Rendimento e dividendo (futuro) | 1,36 (1,13%) |
| Data ex dividendo | 26 apr 2024 |
| Stima target 1A | 125,30 |
GlobeNewswireClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio. “We are extremely excited to partner with UCB, a global biopharmaceutical leader, with a focus on inno
© 2024 Yahoo. Tutti i diritti riservati.